Cargando…
Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers
Prostate cancer (PCa) is one of the most frequently diagnosed cancers and a leading cause of death among men worldwide. Despite extensive efforts in biomarker discovery during the last years, currently used clinical biomarkers are still lacking enough specificity and sensitivity for PCa early detect...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468766/ https://www.ncbi.nlm.nih.gov/pubmed/30857149 http://dx.doi.org/10.3390/metabo9030048 |
_version_ | 1783411509042348032 |
---|---|
author | Gómez-Cebrián, Nuria Rojas-Benedicto, Ayelén Albors-Vaquer, Arturo López-Guerrero, José Antonio Pineda-Lucena, Antonio Puchades-Carrasco, Leonor |
author_facet | Gómez-Cebrián, Nuria Rojas-Benedicto, Ayelén Albors-Vaquer, Arturo López-Guerrero, José Antonio Pineda-Lucena, Antonio Puchades-Carrasco, Leonor |
author_sort | Gómez-Cebrián, Nuria |
collection | PubMed |
description | Prostate cancer (PCa) is one of the most frequently diagnosed cancers and a leading cause of death among men worldwide. Despite extensive efforts in biomarker discovery during the last years, currently used clinical biomarkers are still lacking enough specificity and sensitivity for PCa early detection, patient prognosis, and monitoring. Therefore, more precise biomarkers are required to improve the clinical management of PCa patients. In this context, metabolomics has shown to be a promising and powerful tool to identify novel PCa biomarkers in biofluids. Thus, changes in polyamines, tricarboxylic acid (TCA) cycle, amino acids, and fatty acids metabolism have been reported in different studies analyzing PCa patients’ biofluids. The review provides an up-to-date summary of the main metabolic alterations that have been described in biofluid-based studies of PCa patients, as well as a discussion regarding their potential to improve clinical PCa diagnosis and prognosis. Furthermore, a summary of the most significant findings reported in these studies and the connections and interactions between the different metabolic changes described has also been included, aiming to better describe the specific metabolic signature associated to PCa. |
format | Online Article Text |
id | pubmed-6468766 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64687662019-04-22 Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers Gómez-Cebrián, Nuria Rojas-Benedicto, Ayelén Albors-Vaquer, Arturo López-Guerrero, José Antonio Pineda-Lucena, Antonio Puchades-Carrasco, Leonor Metabolites Review Prostate cancer (PCa) is one of the most frequently diagnosed cancers and a leading cause of death among men worldwide. Despite extensive efforts in biomarker discovery during the last years, currently used clinical biomarkers are still lacking enough specificity and sensitivity for PCa early detection, patient prognosis, and monitoring. Therefore, more precise biomarkers are required to improve the clinical management of PCa patients. In this context, metabolomics has shown to be a promising and powerful tool to identify novel PCa biomarkers in biofluids. Thus, changes in polyamines, tricarboxylic acid (TCA) cycle, amino acids, and fatty acids metabolism have been reported in different studies analyzing PCa patients’ biofluids. The review provides an up-to-date summary of the main metabolic alterations that have been described in biofluid-based studies of PCa patients, as well as a discussion regarding their potential to improve clinical PCa diagnosis and prognosis. Furthermore, a summary of the most significant findings reported in these studies and the connections and interactions between the different metabolic changes described has also been included, aiming to better describe the specific metabolic signature associated to PCa. MDPI 2019-03-08 /pmc/articles/PMC6468766/ /pubmed/30857149 http://dx.doi.org/10.3390/metabo9030048 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Gómez-Cebrián, Nuria Rojas-Benedicto, Ayelén Albors-Vaquer, Arturo López-Guerrero, José Antonio Pineda-Lucena, Antonio Puchades-Carrasco, Leonor Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers |
title | Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers |
title_full | Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers |
title_fullStr | Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers |
title_full_unstemmed | Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers |
title_short | Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers |
title_sort | metabolomics contributions to the discovery of prostate cancer biomarkers |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468766/ https://www.ncbi.nlm.nih.gov/pubmed/30857149 http://dx.doi.org/10.3390/metabo9030048 |
work_keys_str_mv | AT gomezcebriannuria metabolomicscontributionstothediscoveryofprostatecancerbiomarkers AT rojasbenedictoayelen metabolomicscontributionstothediscoveryofprostatecancerbiomarkers AT alborsvaquerarturo metabolomicscontributionstothediscoveryofprostatecancerbiomarkers AT lopezguerrerojoseantonio metabolomicscontributionstothediscoveryofprostatecancerbiomarkers AT pinedalucenaantonio metabolomicscontributionstothediscoveryofprostatecancerbiomarkers AT puchadescarrascoleonor metabolomicscontributionstothediscoveryofprostatecancerbiomarkers |